...
首页> 外文期刊>Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus >Radiotherapy improves the survival of patients with metastatic esophageal squamous cell carcinoma: a propensity score matched analysis of Surveillance, Epidemiology, and End Results database
【24h】

Radiotherapy improves the survival of patients with metastatic esophageal squamous cell carcinoma: a propensity score matched analysis of Surveillance, Epidemiology, and End Results database

机译:放射疗法改善了转移性食管鳞状细胞癌的患者的存活:倾向评分匹配的监测,流行病学和最终结果数据库分析

获取原文
获取原文并翻译 | 示例

摘要

The survival advantage of radiotherapy (RT) for patients with metastatic esophagus cancer has not been adequately evaluated. This study aims to find out the role of RT for metastatic esophagus cancer and to find the different effect for RT to esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC). This study included 5,970 metastatic esophagus cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database, registered from January 2004 to December 2013. Propensity score (PS) analysis with 1:1 nearest neighbor matching method was used to ensure well-balanced characteristics of all comparison groups by histological types. The Kaplan-Meier and Cox proportional hazardous models were used to evaluate the overall survival (OS), cancer-specific survival (CSS), and corresponding 95% confidence interval (CI). Generally speaking, EAC did not get survival benefit from RT (median OS for RT group vs. no-RT group—8.0, 7.6-8.4 vs. 9.0, 8.5-9.5, P = 0.073), whereas RT for metastatic ESCC did significantly improve OS (median OS for RT group vs. no-RT group—8.0, 7.4-8.6 vs. 7.0, 6.4-7.6, P = 0.044). Therefore, compared with adenocarcinoma, ESCC could get more survival benefit from RT.
机译:放射治疗(RT)的存活优势尚未得到充分评估转移性食管癌患者的患者。本研究旨在了解RT用于转移性食道癌的作用,并找到RT对食管腺癌(EAC)和食管鳞状细胞癌(ESCC)的不同效果。本研究包括来自2004年1月至2013年12月的监测,流行病学和最终结果(SEER)数据库的5,970个转移性食道癌症患者,从2013年1月到12月。使用1:1最近的邻居匹配方法的倾向评分(PS)分析来确保良好组织学类型所有比较群的平衡特征。 Kaplan-Meier和Cox比例危险模型用于评估整体存活(OS),癌症特异性存活率(CSS),以及相应的95%置信区间(CI)。一般来说,EAC没有从RT获得生存益处(RT组的中位OS与NO-8.0,7.6-8.4对9.0,8.5-9.5,P = 0.073),而转移ESCC的RT显着改善OS(RT组中位OS与NO-RT组-8.0,7.4-8.6对7.0,6.4-7.6,P = 0.044)。因此,与腺癌相比,ESCC可以从RT获得更多的生存益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号